Aizhan Surumbayeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aizhan Surumbayeva has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Igor Astsaturov
Fox Chase Cancer Center, Philadelphia, USA
24 shared publications - Charline Ogier
The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania
21 shared publications - Diana Restifo
Fox Chase Cancer Center, Philadelphia, PA
21 shared publications - Elizabeth A. Handorf
Rutgers University, Rutgers Cancer Institute, New Brunswick, NJ, USA
20 shared publications - Kathy Q. Cai
Fox Chase Cancer Center 1 Philadelphia, PA
20 shared publications - Aditya Kulkarni
Lantern Pharma Inc., Dallas, Texas
19 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Springer Nature in Nature Cancer
- p. 1-22
ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression
- 30 October 2026
- Published by Springer Nature in Nature Cancer
- p. 1-22
Open AccessANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary Table 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary Table 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figures and tables legends from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary figure legends and Tables
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figures and tables legends from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary figure legends and Tables
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary Table 1 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary Table 1 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
- 28 October 2025
- Published by Wiley in Journal of Cellular Physiology
- Vol. 240 (10) , e70104
Overeating: A Conundrum of Lipid Metabolism and Inflammation in Obesity and Cancer
The global rise in obesity has coincided with an alarming increase in early‐onset cancers and other chronic noncommunicable diseases, underscoring the urgent need to understand the underlying mechanisms linking excess body weight with disease pathogenesis. While genetic factors account for disease risk, environmental and dietary influences, particularly those associated with Western hypercaloric diets, play a dominant role in shaping metabolic health. Obesity‐driven insulin resistance and chronic inflammation are now recognized as central contributors to a wide range of pathologies, including cardiovascular disease, type 2 diabetes, fatty liver, and multiple cancer types. Emerging evidence suggests that disrupted insulin signaling, altered lipid metabolism, and chronic inflammation converge to promote a tumor‐permissive tissue microenvironment. This review examines the mechanistic links between insulin signaling, lipid metabolism, and inflammation as the causality of increased cancer risk in obesity.
- 28 October 2025
- Published by Wiley in Journal of Cellular Physiology
- Vol. 240 (10) , e70104
Overeating: A Conundrum of Lipid Metabolism and Inflammation in Obesity and Cancer
The global rise in obesity has coincided with an alarming increase in early‐onset cancers and other chronic noncommunicable diseases, underscoring the urgent need to understand the underlying mechanisms linking excess body weight with disease pathogenesis. While genetic factors account for disease risk, environmental and dietary influences, particularly those associated with Western hypercaloric diets, play a dominant role in shaping metabolic health. Obesity‐driven insulin resistance and chronic inflammation are now recognized as central contributors to a wide range of pathologies, including cardiovascular disease, type 2 diabetes, fatty liver, and multiple cancer types. Emerging evidence suggests that disrupted insulin signaling, altered lipid metabolism, and chronic inflammation converge to promote a tumor‐permissive tissue microenvironment. This review examines the mechanistic links between insulin signaling, lipid metabolism, and inflammation as the causality of increased cancer risk in obesity.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies
Supplementary Table 2 from Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies
Supplementary Table 2 from Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies
The greater efficacy of DNA-damaging drugs for pancreatic adenocarcinoma (PDAC) relies on targeting cancer-specific vulnerabilities while sparing normal organs and tissues due to their inherent toxicities. We tested LP-184, a novel acylfulvene analog, for its activity in preclinical models of PDAC carrying mutations in the DNA damage repair (DDR) pathways. Cytotoxicity of LP-184 is solely dependent on prostaglandin reductase 1 (PTGR1), so that PTGR1 expression robustly correlates with LP-184 cytotoxicity in vitro and in vivo. Low-passage patient-derived PDAC xenografts with DDR deficiencies treated ex vivo are more sensitive to LP-184 compared to DDR-proficient tumors. Additional in vivo testing of PDAC xenografts for their sensitivity to LP-184 demonstrates marked tumor growth inhibition in models harboring pathogenic mutations in ATR, BRCA1 and BRCA2. Depletion of PTGR1, however, completely abrogates the anti-tumor effect of LP-184. Testing combinatorial strategies for LP-184 aimed at deregulation of nucleotide excision repair proteins ERCC3 and ERCC4 established synergy. Our results provide valuable biomarkers for clinical testing of LP-184 in a large subset of genetically defined characterized refractory carcinomas. High PTGR1 expression and deleterious DDR mutations are present in approximately one third of PDAC making these patients ideal candidates for clinical trials of LP-184.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies
The greater efficacy of DNA-damaging drugs for pancreatic adenocarcinoma (PDAC) relies on targeting cancer-specific vulnerabilities while sparing normal organs and tissues due to their inherent toxicities. We tested LP-184, a novel acylfulvene analog, for its activity in preclinical models of PDAC carrying mutations in the DNA damage repair (DDR) pathways. Cytotoxicity of LP-184 is solely dependent on prostaglandin reductase 1 (PTGR1), so that PTGR1 expression robustly correlates with LP-184 cytotoxicity in vitro and in vivo. Low-passage patient-derived PDAC xenografts with DDR deficiencies treated ex vivo are more sensitive to LP-184 compared to DDR-proficient tumors. Additional in vivo testing of PDAC xenografts for their sensitivity to LP-184 demonstrates marked tumor growth inhibition in models harboring pathogenic mutations in ATR, BRCA1 and BRCA2. Depletion of PTGR1, however, completely abrogates the anti-tumor effect of LP-184. Testing combinatorial strategies for LP-184 aimed at deregulation of nucleotide excision repair proteins ERCC3 and ERCC4 established synergy. Our results provide valuable biomarkers for clinical testing of LP-184 in a large subset of genetically defined characterized refractory carcinomas. High PTGR1 expression and deleterious DDR mutations are present in approximately one third of PDAC making these patients ideal candidates for clinical trials of LP-184.